ZNF217

Across TCGA pan-cancer cohorts, ZNF217 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF217 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZNF217 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF217 expression acts as an unfavorable survival marker, although some lineages such as OV and HNSC show a favorable association.

PDAC, CCRCC, and OV are the cancer types where ZNF217 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.304	0.564	<.001	81	view →
CCRCC	OS	Median	II,III,IV	0.774	1.000	.003	54	view →
OV	DFS	Tertile	All	0.884	0.438	.032	16	view →
HNSC	DFS	Median	III,IV	1.000	0.903	.004	14	view →
LUAD	DFS	Median	II,III,IV	1.000	0.798	.015	8	view →
GBM	DFS	Tertile	All	0.480	0.313	.039	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZNF217–PDAC (DFS)

Open the PDAC breakdown →